



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/520,791-Conf. #3248
				Filing Date	January 8, 2005
				First Named Inventor	Alexander Dömling
				Art Unit	1645
				Examiner Name	S. Gudibande
Sheet	1	of	1	Attorney Docket Number	62660(52171)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
AA*	US-2005-0239713-A1	10-27-2005	R&D-Biopharmaceuticals GmbH		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		
BA	WO-98-13375-A	04-02-1998	Biotechnolog Forschung GmbH		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ CITE NO.: Those application(s) which are marked with an single asterisk () next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			⁷
<i>S</i>	CA	Sasse, F. et al. "Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli production, isolation, physico-chemical and biological properties" <i>Journal of Antibiotics</i> , Japan Antibiotics Research Association, Bd. 53, Nr. 9, Sept. 2000, Seiten 879-885, XP009014740.			
<i>S</i>	CB	Greenwald, R.B. "PEG drugs: an overview" <i>Journal of Controlled Release</i> , Elsevier Science Publishers B.V. Amsterdam, NL, Bd. 74, Nr.1-3, July 6, 2001, Seiten 159-171, XP004297521.			
<i>S</i>	CC	Duncan R. et al. "Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic" <i>Journal of Controlled Release</i> , Elsevier Science Publishers B.V. Amsterdam, NL, Bd. 74, NR. 1-3, July 6, 2001, Seiten 135-146, XP004297519.			
<i>S</i>	CD	Garnett, M. C. "Targeted drug conjugates: Principles and progress" <i>Advanced Drug Delivery Reviews</i> , Bd. 53, Nr. 2, Dec. 17, 2001, Seiten 171-216, XP002261805.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ⁷Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 520064	<i>Kathy</i>	Date Considered	1/17/06
------------------------------	--------------	-----------------	---------